Enzo Biochem EPS - Earnings per Share 2010-2022 | ENZ

Enzo Biochem eps - earnings per share from 2010 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Enzo Biochem Annual EPS
2021 $0.16
2020 $-0.60
2019 $0.05
2018 $-0.22
2017 $-0.05
2016 $0.97
2015 $-0.05
2014 $-0.23
2013 $-0.46
2012 $-1.01
2011 $-0.34
2010 $-0.59
2009 $-0.63
Enzo Biochem Quarterly EPS
2022-01-31 $-0.05
2021-10-31 $-0.05
2021-07-31 $0.06
2021-04-30 $0.04
2021-01-31 $0.05
2020-10-31 $0.01
2020-07-31 $-0.07
2020-04-30 $-0.21
2020-01-31 $-0.16
2019-10-31 $-0.16
2019-07-31 $-0.11
2019-04-30 $0.47
2019-01-31 $-0.18
2018-10-31 $-0.13
2018-07-31 $-0.13
2018-04-30 $-0.06
2018-01-31 $-0.02
2017-10-31 $-0.01
2017-07-31 $0.00
2017-04-30 $0.00
2017-01-31 $-0.02
2016-10-31 $-0.03
2016-07-31 $0.77
2016-04-30 $-0.05
2016-01-31 $0.15
2015-10-31 $0.10
2015-07-31 $0.18
2015-04-30 $-0.06
2015-01-31 $-0.09
2014-10-31 $-0.08
2014-07-31 $-0.06
2014-04-30 $-0.01
2014-01-31 $-0.09
2013-10-31 $-0.07
2013-07-31 $-0.08
2013-04-30 $-0.15
2013-01-31 $-0.14
2012-10-31 $-0.09
2012-07-31 $-0.69
2012-04-30 $-0.09
2012-01-31 $-0.11
2011-10-31 $-0.12
2011-07-31 $-0.11
2011-04-30 $-0.05
2011-01-31 $-0.15
2010-10-31 $-0.03
2010-07-31 $-0.15
2010-04-30 $-0.12
2010-01-31 $-0.27
2009-10-31 $-0.05
2009-07-31 $-0.15
2009-04-30 $-0.11
2009-01-31 $-0.20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.118B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00